Academic Journal
Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients ( n =647) with primary breast cancer:A Danish Breast Cancer Cooperative Group Study
| العنوان: | Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients ( n =647) with primary breast cancer:A Danish Breast Cancer Cooperative Group Study |
|---|---|
| المؤلفون: | Willemoe, Gro L., Hertel, Pernille Bræmer, Bartels, Annette, Jensen, Maj-Britt, Balslev, Eva, Rasmussen, Birgitte B., Mouridsen, H T, Ejlertsen, Bent Laursen, Brunner, Nils |
| المصدر: | Willemoe , G L , Hertel , P B , Bartels , A , Jensen , M-B , Balslev , E , Rasmussen , B B , Mouridsen , H T , Ejlertsen , B L & Brunner , N 2009 , ' Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients ( n =647) with primary breast cancer : A Danish Breast Cancer Cooperative Group Study ' , European Journal of Cancer , vol. 45 , no. 14 , pp. 2528-2536 . https://doi.org/10.1016/j.ejca.2009.05.029 |
| سنة النشر: | 2009 |
| المجموعة: | University of Copenhagen: Research / Forskning ved Københavns Universitet |
| الوصف: | PURPOSE: A number of prospective studies have shown that adjuvant CEF significantly improves disease-free and overall survival as compared to CMF in breast cancer patients. Our aim was to determine whether the benefit of epirubicin versus methotrexate differs according to TIMP-1 tumour cell immunoreactivity. EXPERIMENTAL DESIGN: Tissue micro arrays from 647 patients randomly assigned to CMF or CEF in DBCG trial 89D were included. The primary end-point was invasive disease-free survival (IDFS). A central assessment of tissue inhibitor of metalloproteinases 1 (TIMP-1) status was performed using immunohistochemistry (IHC). Tumours were regarded as TIMP-1 positive if epithelial breast cancer cells were stained using the anti-TIMP-1 monoclonal antibody VT7. RESULTS: By central assessment 75% of tumours were classified as tumour cell TIMP-1 positive. Among CEF-treated patients, individuals with TIMP-1 negative tumours had a significant longer IDFS than patients with TIMP-1 positive tumours (p=0.047). The multivariate Cox regression analysis of IDFS showed that CEF was superior to CMF among patients with TIMP-1 negative tumours (hazard ratio (HR)=0.51; 95% confidence interval (CI): 0.31-0.84, p=0.0085), while no significant difference could be demonstrated among patients with TIMP-1 positive tumours (HR=0.88; 95% CI: 0.68-1.13, p=0.32). A non-significant TIMP-1 status (positive or negative) versus treatment (CMF or CEF) interaction was detected for IDFS (p=0.06) and OS (p=0.21). CONCLUSION: Lack of TIMP-1 tumour cell immunoreactivity seems to predict a favourable effect of epirubicin-containing adjuvant therapy in primary breast cancer. However, an independent study is awaited to validate the potential predictive value of TIMP-1 immunoreactivity |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1016/j.ejca.2009.05.029 |
| الاتاحة: | https://curis.ku.dk/portal/da/publications/lack-of-timp1-tumour-cell-immunoreactivity-predicts-effect-of-adjuvant-anthracyclinebased-chemotherapy-in-patients-n647-with-primary-breast-cancer(055334d0-5cfb-11df-928f-000ea68e967b).html https://doi.org/10.1016/j.ejca.2009.05.029 |
| Rights: | info:eu-repo/semantics/restrictedAccess |
| رقم الانضمام: | edsbas.992C06C5 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.ejca.2009.05.029 |
|---|